Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
09:05am, Thursday, 17'th Oct 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
07:06pm, Tuesday, 15'th Oct 2024
Gilead Sciences (GILD) reachead $85.83 at the closing of the latest trading day, reflecting a +0.91% change compared to its last close.
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
10:50am, Friday, 11'th Oct 2024
GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted population.
Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.
08:00am, Friday, 11'th Oct 2024
None of our picks is Nvidia or Apple or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
08:30am, Wednesday, 09'th Oct 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek 2024
Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know
07:06pm, Tuesday, 08'th Oct 2024
Gilead Sciences (GILD) reachead $85.21 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation
09:58am, Saturday, 05'th Oct 2024
Gilead's lenacapavir may become a blockbuster HIV prophylactic. Biktarvy maintains a dominant market share in the HIV treatment space, contributing significantly to Gilead's revenue growth. Gilead's o
GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
01:10pm, Thursday, 03'rd Oct 2024
Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its investigational medicine, lenacapavir, for HIV Prevention.
Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda
11:29am, Thursday, 03'rd Oct 2024
Gilead Sciences said on Thursday it would donate about 5,000 vials of its antiviral remdesivir to the Rwanda Medical Supply for emergency use in response to the Marburg virus disease outbreak.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
10:05am, Thursday, 03'rd Oct 2024
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
12:55pm, Wednesday, 02'nd Oct 2024
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and lower-m
- Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-experienced patients with multi drug-resista
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufac
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
07:06pm, Tuesday, 01'st Oct 2024
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $83.94, denoting a +0.12% change from the preceding trading day.
2 Top Picks With Contrarian Potential as Q4 Looms
09:58am, Tuesday, 01'st Oct 2024
Subscribers to Chart of the Week received this commentary on Sunday, September 29.
